A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Financial Summary
| Share Statistics | VBIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.0 | $252.6 | 1% |
|
| Shares Out (Mil) | 2.9 | 52.3 | 10% |
|
| Institutional Ownership | 75.2% | 92.1% | 45% |
|
| Float (Mil) | 2.6 | 40.2 | 6% |
|
| Beta | 1.80 | 0.95 | 89% |
|
| Avg Daily Volume (000s) | 1,525 | 455 | 77% |
|
| Price Change (52-week) |
(91.4%) | 52.9% | 4% |
|
| Growth | VBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (19.8%) | (9.9%) | 20% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | VBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($14) | ($43) | 27% |
|
| EPS (TTM) | ($7.996) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($11) | ($31) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $17 | $5 | 31% |
|
| Enterprise Value (Q1) (Mil) | $12 | $180 | 8% |
|
| Valuation | VBIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.08 | 2.56 | 1% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | VBIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (64.7%) | (49.8%) | 9% |
|
| ROE | (192.6%) | (55.5%) | 5% |
|
| Liabilities to Assets | 71.1% | 30.3% | 66% |
|
| F-Score | 2 | 3 | na |
|
Valion Bio, Inc. did not pass any screens on 7/31/2026.
